Generics

Study shows that anti-detailing policies can increase generic prescribing.

Generic drug prevents post-birth bleeding deaths

Nearly 20 health-care organizations and PBMs come out in favor of FAST Generics Act.

Drug spending is going down at CVS Caremark. Here’s why.

California judge blocks 11 classes in suit that claims CVS charged insurers and insured patients more than uninsured patients.

FDA set a record for generics approval, but is the process still too cumbersome?

A $96.5 million settlement is the latest in a series of pricing and competition issues Mylan has faced in the past year.

More biosimilars are coming onto the market , including competitors for Remicade and Neulasta.

The urgent need for a less-expensive epinephrine auto-injector is now being addressed.

If pharma is “getting away with murder” with drug pricing, more generic and biosimilars can help control costs, says this group.

The prices of heart failure drugs at retail pharmacies vary widely, and uninsured patients may not be able to afford them, researchers have found.

At a time when biosimilars are of strong interest to insurers and health care systems for cost control, physicians are not rushing to issue a blank check for their substitution. Details here.

Two new biosimilar announcements are expected to increase the uptake of the biosimilar infliximab to Johnson & Johnson’s Remicade for rheumatoid arthritis, Crohn’s disease, and other inflammatory conditions.

Generic drugs produced $227 billion in savings for the U.S. healthcare system in 2015

While FDA recently approved two new biosimilars for rheumatoid arthritis and other inflammatory diseases, questions remain about how quickly physicians and patients will embrace the new drugs.

Generic drugmakers and others are pushing for faster FDA approval of generics.

An exclusive Associated Press report found that Medicare’s spending on certain drugs soared by 85% in two years.

Physicians and pharmacists welcomed FDA’s recent approval of etanercept-szzs (Erelzi), a biosimilar to Amgen’s top-selling Enbrel for rheumatoid arthritis, plaque psoriasis, and other inflammatory conditions.

FDA’s method for naming biosimilars and interchangeable biologics came under fire long before the first biosimilar, Zarxio, was approved last spring.

New study finds that biosimilar medications for arthritis and other diseases areas safe and effective as their brand-name counterparts.

Generic drug price hikes are not likely to disappear anytime soon. Find out why they're occurring and what can be done about them.

Patents expire, competition rises, and outsourcing expands.

The CREATES Act came about because some pharmaceutical manufacturers are misusing the REMS program to prevent generic drug development.

Walmart has decided to put all its eggs in a really big basket.

PBMs have dodged state-mandated requirements for transparency in generics drug pricing, so many states are rewriting their laws.

While many groups are criticizing the FDA backlog of generic drug approvals, the agency has released the numbers on approvals and tentative approvals for 2015.

Five years of imatinib treatment for CML = >$100,000 saved per patient.

The use of biosimilars in the European Union and the United States may yield huge savings to healthcare systems over the next five years

Physicians are beginning to understand the value of biosimilars, particularly those who are high prescribers of biologics and therefore familiar with biosimilars.

Sixteen members of Congress are urging passage of the MAC Transparency Act and greater reimbursement transparency for the big federal health programs.